





19th CardioVascular Summit: TCTAP 2014often unavoidable. During this period, coronary collateral circulation be an important
alternative supply when the main blood vessels fail to provide adequate perfusion to
myocardial tissues due to occlusion. This study aims to determine the effect of
collateral circulation in MR Imaging-Veriﬁed Myocardial infarct size and myocardial
salvage index (MSI) in the acute phase of STEMI treated with PPCI.
Methods: Study was designed as cross-sectional study involving 33 STEMI patients
with symptoms < 12 hours who underwent successful PPCI. Samples were taken
consecutively from November 2012 to April at the National Cardiovascular Center
Harapan Kita Jakarta. Collateral ﬂow was gradded regarding to Rentrop classiﬁcation.
Patients were divided into 2 groups; Group A had absent or weak collateral ﬂow and
group B had signiﬁcant ﬂow. All patients underwent cardiac magnetic resonance
(CMR) to assess infarct size and MSI.
Results: In our study, 12out of 33 (36%) patients had signiﬁcant collateral circulation
(Rentrop grade2 or 3). Pre-infarction angina was a clinicalfactors associated with
recruitable collaterals(p<0,001). Infarct size expressed as percent LV mass (IS%LV)
was signiﬁcantly smaller in group B (14.2%vs. 23.3%; p ¼ 0.036). Extent of MSI was
signiﬁcantly higher in group B (0,6 vs 0,1; p<0,001).
Conclusion: Well-developed collaterals before reperfusion by PPCI in patients with
STEMI are associated with a protective effect on infarct size and MSI.Antiplatelet Agents and Anticoagulants
(TCTAP A-027 to TCTAP A-036)
TCTAP A-027
Comparison of On-treatment Platelet Reactivity After One-month Use of
Clopidogrel, Prasugrel or Ticagrelor in Koreans with Acute Coronary
Syndromes
Ji Hyun Lee, Sung Gyun Ahn, Jun-Won Lee, Young Jin Youn, Min-Soo Ahn,
Jang-Young Kim, Byung-Su Yoo, Seung-Hwan Lee, Junghan Yoon
Wonju Severance Christian Hospital, Wonju, Korea (Republic of)
Background: Prasugrel and ticagrelor have greater anti-ischemic efﬁcacy than clo-
pidogrel, but they are not widely used in East Asia owing to their increased risk of
bleeding. We compared on-treatment platelet reactivity (OPR) of these 3 drugs after 1
month in patients with acute coronary syndromes (ACS).
Methods:We assigned 95 patients undergoing percutaneous coronary intervention for
ACS to clopidogrel, prasugrel, or ticagrelor treatment. We measured OPR using the
VerifyNow P2Y12 assay. High OPR (HOPR) was deﬁned by P2Y12 reaction unit
(PRU) 240; low OPR (LOPR) was deﬁned by PRU <85. We compared the numbers
of patients with HOPR and LOPR after 1 month of antiplatelet treatment.
Results: OPR was lowest in the ticagrelor group (n¼25), followed by the pra-
sugrel (n¼34) and clopidogrel groups (n¼36, 4930 vs 8659 vs 17977,
p <0.001). HOPR was not noted in the prasugrel or ticagrelor groups, but was
noted in 5 clopidogrel-treated patients (13.9%, p¼0.007). The ticagrelor group
had the most number of patients with LOPR, followed by the prasugrel and
clopidogrel groups (88% vs 52.9% vs 13.9%, p <0.001). The clopidogrel
group had the highest number of patients in the therapeutic window of OPR (PRU
85–239) (Figure).Conclusion: HOPR to clopidogrel can be overcome by using prasugrel or ticagrelor.
However, prasugrel or ticagrelor increased LOPR, which may lead to excessive
bleeding events in East Asians.S8 JACC Vol 63/12/Suppl S j April 22–25, 2TCTAP A-028
Comparison of Platelet Aggregation Before & After Loading Dose of Prasugrel
and Clopidogrel in Percutaneous Coronary Intervention in Adult Pakistani
Coronary Artery Disease Patients
Ahmad Shahbaz1, Ahmad Nouman1, Khawar Mehdi2, Muhammad Azhar1
1PIC, Karachi, Pakistan, 2Getz Pharma, Karachi, Pakistan
Background: The use of dual antiplatelet therapy with aspirin and a thienopyridine is an
essential aspect of the supportive pharmacologic regimen administered to coronary artery
disease (CAD) patients who are undergoing primary percutaneous coronary intervention
(PCI). This study was carried out to compare the inhibition of platelet aggregation (IPA)
between prasugrel and clopidogrel in adult Pakistani patients undergoing primary PCI.
Methods: A total of hundred subjects were randomly assigned to two groups A & B.
GroupA (n¼50) received prasugrel (PRISA) 60mg loading dose pre PCI and 10mgQD
maintenance dose, whereas group B (n¼50) received clopidogrel 600mg loading and 75
mg BID maintenance dose respectively. Adenosine diphospahte (ADP) was used as
agonist before loading dose and post-PCI at 3-4 hours since it is themost commonly used
agonist, particularly in systems that measure only platelet aggregation in whole blood.
Results: Male and female ratio was 4:1 in both groups. Mean age was insigniﬁcant
between group A and group B (50.39.6 vs. 50.310.9; range: 29-68 and 23-71 years
respectively). In Group A (Prasugrel) n¼50; the respective occurrence of CAD was:
LAD n¼25 (50%), RCA n¼14 (28%), Cx Distal n¼5 (10%), MVD n¼3 (6%), Non-
stent 1 (2%) & others n¼2 (4%). In Group B (Clopidogrel) n¼50; the respective
occurrence of CADwas: LAD n¼23 (46%), RCA n¼11 (22%),MVD n¼8 (16%)&Cx
Distal n¼7 (14%) & others n¼1 (2%). None of the patient experienced minor or major
adverse cardiac events after taking loading dose in both groups. The before and after
loading dose mean platelet aggregation (MPA) responses were statistically signiﬁcant
within the two treatment groups (Group A: 6.082.12 vs 1.562.11; p<0.001 and
Group B: 4.272.06 vs 0.681.38; p<0.001). The mean reduction in platelet aggre-
gation by Group A (Prasugrel) was 74.4% and by Group B (Clopidogrel) was 51.8%.
Conclusion: Prasugrel 60 mg loading dose (PRISA) achieves signiﬁcantly greater
IPA as compared to clopidogrel 600 mg LD. Both drugs were well-tolerated and
adverse drug reactions were comparable.
TCTAP A-029
Low Dose Proton Pump Inhibitors in Patients Treated with Dual-antiplatelet
Therapy After Acute Coronary Syndrome
Yoshiki Nagata, Takuya Mayumi, Tomoya Harada, Masaki Kinoshita,
Isao Aburadani, Motoaki Hirazawa, Michiro Maruyama, Kazuo Usuda
Toyama Prefectural Central Hospital, Toyama, Japan
Background: The proton pump inhibitors (PPIs) with aspirin and clopidogrel are
frequently concomitantly used to prevent adverse gastrointestinal effects. However, it has
been reported that the antiplatelet action becomes attenuated when a PPI is used in com-
bination with clopidogrel. The Food and Drug Administration issued a warning against the
concomitant use of high dose (40 mg) esomeprazole/omeprazole with clopidogrel. This
warning has raised concerns that the addition of a PPI to clopidogrel in acute coronary
syndrome (ACS)patients could actually increase the risk of recurrent cardiovascular events.
Methods: The effect of PPIs causing platelet aggregation during the administration of
clopidogrel was investigated after primary percutaneous coronary intervention (PCI).
The subjects consisted of 122 cases of ACS. Platelet aggregation function testing
(light transmission intensity method) was conducted while aspirin and clopidogrel
75mg were orally taken before discharge. The minimum concentration of aggregation
induction (Platelet aggregation threshold index; PATI) was measured. The PATI,
measured with ADP as the inducing substance, was compared and investigated ac-
cording to the type of concomitantly used PPIs.
Results: The result of the PATI were: non-PPI group: 3.730.62 mM (N¼18) and PPI
group: 3.330.94mM (N¼104). The difference of type of PPI were rabeprazole (10
mg) group: 3.630.63 mM (N¼20), esomeprazole (20 mg) group 3.310.93 (N¼39)
and lansoprazole (15 mg) group: 3.211.06 mM (N¼42). The omeprazole group was
excluded, because the subjects were only 3 cases. The PATI of lansoprazole group
was the lower than the other groups (p <0.05 compared with non-PPI group).
Conclusion: The effect of CYP2C19 differs depending on the type of PPI, with a
difference being caused in the interaction with clopidogrel. The concomitant use of
low dose lansoprazole reduced the antiplatelet action of clopidogrel. The low dose
esomeprazole reduced the antiplatelet action, but the interaction effect was small.
Rabeprazole was least inﬂuence on the antiplatelet action. When PPI is used in
combination with dual-antiplatelet therapy in ACS patients, low dose esomeprazole
and rabeprazole should be consideration.
TCTAP A-030
Safety and Efﬁcacy of a Hybrid Dual Antiplatelet Therapy Regimen for ST-
elevation Myocardial Infarction Patients: A Single-centre Experience
Deanna Khoo, Yee May Wong, Hee Hwa Ho, Yau Wei Ooi, Paul Jau, Lueng Ong,
Fahim Haider Jafary, Kwok Kong Loh, Julian Tan, David Foo
Tan Tock Seng Hospital, Singapore, Singapore
Background: Prasugrel, a third generation thienopyridine is recognised as one of the
cornerstone treatment of contemporary dual antiplatelet therapy (DAPT) in selected
patients with ST- elevation myocardial infarction (STEMI) undergoing primary
percutaneous coronary intervention (PPCI). The incremental cost of prasugrel coupled014 j TCTAP Abstracts/ORAL/Antiplatelet Agents and Anticoagulants
